Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease
Authors
Keywords
-
Journal
Diabetology International
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-02-19
DOI
10.1007/s13340-023-00619-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metabolic dysfunction‐associated fatty liver disease directly related to liver fibrosis independent of insulin resistance, hyperlipidemia, and alcohol intake in morbidly obese patients
- (2022) Susumu Inamine et al. HEPATOLOGY RESEARCH
- Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial
- (2021) Giuseppe Della Pepa et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients
- (2021) Jee-Fu Huang et al. Hepatology International
- Similarities and Differences: A Comparative Review of the Molecular Mechanisms and Effectors of NAFLD and AFLD
- (2021) Pengyi Zhang et al. Frontiers in Physiology
- Reduced alcohol use in patients prescribed pioglitazone
- (2021) Eric Dieperink et al. AMERICAN JOURNAL ON ADDICTIONS
- Causes of mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol related Fatty Liver Disease (AFLD).
- (2020) Michael P Johnston et al. CURRENT PHARMACEUTICAL DESIGN
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- What's in a name? Renaming ‘NAFLD’ to ‘MAFLD’
- (2020) Yasser Fouad et al. LIVER INTERNATIONAL
- Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map
- (2020) Jai Kumar et al. DIGESTIVE AND LIVER DISEASE
- Effect of alcohol consumption and the presence of fatty liver on the risk for incident type 2 diabetes: a population-based longitudinal study
- (2020) Takuro Okamura et al. BMJ Open Diabetes Research & Care
- Hepatocellular carcinoma in the setting of alcohol-related liver disease
- (2019) Nathalie Ganne-Carrié et al. JOURNAL OF HEPATOLOGY
- Alcohol Consumption and Risk of Liver Cirrhosis
- (2019) Michael Roerecke et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
- (2018) Bancha Satirapoj et al. PLoS One
- Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes
- (2017) Christopher E. Shannon et al. FEBS Journal
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Pathogenesis of Alcoholic Liver Disease
- (2016) Winston Dunn et al. Clinics in Liver Disease
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD)
- (2016) Ratree Sawangjit et al. MEDICINE
- Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study
- (2015) Gro Askgaard et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma: clinical frontiers and perspectives
- (2014) Jordi Bruix et al. GUT
- Report of the Japan Diabetes Society/Japanese Cancer Association joint committee on diabetes and cancer
- (2013) Masato Kasuga et al. CANCER SCIENCE
- From NAFLD to NASH to cirrhosis—new insights into disease mechanisms
- (2013) Alexander Wree et al. Nature Reviews Gastroenterology & Hepatology
- Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population
- (2012) Yoshio Sumida et al. BMC GASTROENTEROLOGY
- Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study
- (2012) Lauren N. Bell et al. HEPATOLOGY
- The epidemiology, pathogenesis and histopathology of fatty liver disease
- (2012) Adam P Levene et al. HISTOPATHOLOGY
- Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis
- (2011) E. Boettcher et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Activation of Nuclear PPARγ Receptors by the Antidiabetic Agent Pioglitazone Suppresses Alcohol Drinking and Relapse to Alcohol Seeking
- (2011) Serena Stopponi et al. BIOLOGICAL PSYCHIATRY
- A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease
- (2010) Giovanni Musso et al. HEPATOLOGY
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease
- (2009) Yasuji Arase et al. JOURNAL OF GASTROENTEROLOGY
- Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis
- (2008) Guruprasad P. Aithal et al. GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started